226559-04-2

Upstream product

• 1186382-58-0 C₅₂H₇₁N₉O₁₂S 
• 1186382-57-9 C₅₂H₇₃N₉O₁₃S 
• 35661-40-6 N-Fmoc L-Phe 
• 187618-60-6 Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine 
• 1186382-58-0 C₅₂H₇₁N₉O₁₂S 
• 1186382-57-9 H-Asp(OtBu)-D-Phe-Lys(Z)-Arg(Pbf)-Gly-OH 
• 916826-37-4 C₅₄H₇₇N₉O₁₂S 

Downstream Products

• 696660-84-1 [(2S,5R,8S,11S)-8-[4-((S)-2-Amino-3-hydroxy-propionylamino)-butyl]-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid 
• 343312-28-7 cyclo(-Gly-Asp-D-Phe-Lys(CO-COH)-Arg-) 
• 1351397-23-3 N-α-bis(hydroxycarbonylmethyl)-cyclic(Arg-Gly-Asp-D-Phe-Lys) 

Relevant academic research and scientific papers

OPTIMISED MULTIVALENT TARGETING FLUORESCENT TRACER

A fluorescent tracer comprises: a RAFT template, comprising the residues: Glycine-Proline-Lysine-Alanine-Lysine-Glycine-Proline-Lysine-Lysine-Lysine and having a mean plane defining an upper face having four lysine residues and a lower face having one lysine residue, four identical targeting molecules comprising the amino acids: Arginine-Glycine-Aspartic acid-Phenylalanine-Lysine (RGDKf), each of the molecules being fixed to a different lysine residue of the first upper face via an oxime bond, and a fluorophore S0456 fixed to the lower face of the mean plane via a spacer arm connecting the central carbon of the sequence of double bonds of the fluorophore and the lysine amino acid of the lower face of the decapeptide via an amide bond, the spacer arm being 5-(4-hydroxyphenyl)pentanoic acid.

A novel 2-cyanobenzothiazole-based 18F prosthetic group for conjugation to 1,2-aminothiol-bearing targeting vectors

In a bid to find an efficient means to radiolabel biomolecules under mild conditions for PET imaging, a bifunctional 18F prosthetic molecule has been developed. The compound, dubbed [18F]FPyPEGCBT, consists of a 2-substituted pyridine moiety for [18F]F- incorporation and a 2-cyanobenzothiazole moiety for coupling to terminal cysteine residues. The two functionalities are separated by a mini-PEG chain. [18F]FPyPEGCBT could be prepared from its corresponding 2-trimethylammonium triflate precursor (100 °C, 15 min, MeCN) in preparative yields of 11% ± 2 (decay corrected, n = 3) after HPLC purification. However, because the primary radiochemical impurity of the fluorination reaction will not interact with 1,2-aminothiol functionalities, the 18F prosthetic could be prepared for bioconjugation reactions by way of partial purification on a molecularly imprinted polymer solid-phase extraction cartridge. [18F]FPyPEGCBT was used to 18F-label a cyclo-(RGDfK) analogue which was modified with a terminal cysteine residue (TCEP·HCl, DIPEA, 30 min, 43°C, DMF). Final decay-corrected yields of 18F peptide were 7% ± 1 (n = 9) from end-of-bombardment. This novel integrin-imaging agent is currently being studied in murine models of cancer. We argue that [18F]FPyPEGCBT holds significant promise owing to its straightforward preparation, 'click'-like ease of use, and hydrophilic character. Indeed, the water-tolerant radio-bioconjugation protocol reported herein requires only one HPLC step for 18F peptide purification and can be carried out remotely using a single automated synthesis unit over 124-132 min.

Chemical functionalization of bioceramics to enhance endothelial cells adhesion for tissue engineering

To control the selective adhesion of human endothelial cells and human serum proteins to bioceramics of different compositions, a multifunctional ligand containing a cyclic arginine-glycine-aspartate (RGD) peptide, a tetraethylene glycol spacer, and a gallate moiety was designed, synthesized, and characterized. The binding of this ligand to alumina-based, hydroxyapatite-based, and calcium phosphate-based bioceramics was demonstrated. The conjugation of this ligand to the bioceramics induced a decrease in the nonselective and integrin-selective binding of human serum proteins, whereas the binding and adhesion of human endothelial cells was enhanced, dependent on the particular bioceramics.

Comparing dendritic and self-assembly strategies to multivalency - RGD peptide-integrin interactions

This paper compares covalent and non-covalent approaches for the organisation of ligand arrays to bind integrins. In the covalent strategy, linear RGD peptides are conjugated to first and second generation dendrons, and using a fluorescence polarisation c

COMPOUNDS HAVING RD TARGETING MOTIFS

The present invention provides compounds that have motifs that target the compounds to cells that express integrins. In particular, the compounds have peptides with one or more RD motifs conjugated to an agent selected from an imaging agent and a targetin